B, C, or D bilateral intraocular retinoblastoma.
with Group B disease and a total of 6 courses for patients with Group C or D disease.
every 6 months for 2 years, and then annually for 1 year.
PROJECTED ACCRUAL: A total of 71 patients will be accrued for this study within 2.4 years.